LAVA Therapeutics to Participate at the Jefferies Healthcare Conference

Rhea-AI Summary

LAVA Therapeutics, a clinical stage immuno-oncology company, announced that CEO Stephen Hurly will join a fireside chat at the Jefferies Healthcare Conference in New York on June 9, 2022, from 11:30 to 11:55 a.m. EDT. The discussion will focus on the company's proprietary Gammabody™ platform, designed to enhance cancer treatment through bispecific gamma delta T cell engagers. A live webcast of the event can be accessed on the investor relations section of LAVA's website, with a replay available for 90 days post-event.

UTRECHT, The Netherlands and PHILADELPHIA, June 02, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a fireside chat at the Jefferies Healthcare Conference being held in New York, NY.

Presentation Details
Format: Fireside chat
Date: Thursday, June 9, 2022
Time: 11:30-11:55 a.m. EDT

A live webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at: https://ir.lavatherapeutics.com/news-events/events. A replay will be archived for 90 days following the presentation date.

About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical stage immuno-oncology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid and hematological malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. LAVA-051, the Company’s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study (NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling (NCT05369000). For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.

CONTACTS
Investor Relations
ir@lavatherapeutics.com

Argot Partners (IR/Media)
212-600-1902
lava@argotpartners.com

FAQ

When is LAVA Therapeutics participating in the Jefferies Healthcare Conference?

LAVA Therapeutics will participate in the Jefferies Healthcare Conference on June 9, 2022.

What time will the LAVA Therapeutics fireside chat take place?

The fireside chat will take place from 11:30 to 11:55 a.m. EDT on June 9, 2022.

Who will represent LAVA Therapeutics at the Jefferies Healthcare Conference?

Stephen Hurly, the president and CEO of LAVA Therapeutics, will represent the company.

How can I access the fireside chat for LAVA Therapeutics?

The fireside chat can be accessed via a live webcast on the investor relations section of LAVA Therapeutics' website.

Will there be a replay of the LAVA Therapeutics fireside chat?

Yes, a replay of the fireside chat will be available for 90 days after the event.

What is the purpose of LAVA Therapeutics' Gammabody™ platform?

The Gammabody™ platform aims to develop bispecific gamma delta T cell engagers to improve cancer treatment.